EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Expert Q&A

14. Which contract clauses protect continuity when regulation, price or performance changes?

Dose Diligence research deskSection 06 · Page 17 of 22Last updated 17 Nov 2026

Framing: negotiate the exit process as carefully as the entry price. Manufacturer programme terms reviewed here reserve rights to modify or cancel offers, while FDA’s evolving GLP-1 communications show why a historical access assumption should not underpin an unconditional long-term commitment. (lilly.com)

Put to: Jesse Dresser and Adam Fein.
Buyer owner: Counsel and CFO.

A good answer should cover these proposed negotiation topics:

  • Product-, facility- or state-specific suspension and termination triggers.
  • Treatment of minimum commitments when the agreed route cannot be supplied.
  • Price-change notice, promotion expiry and withdrawal of programme eligibility.
  • Deposits, unused balances, undelivered orders, refunds and replacement costs.
  • Recall, complaint and adverse-event cooperation.
  • Access to operational records and reasonable transition assistance.
  • Responsibility for subcontractors and changes to the dispensing facility.
  • Remedies for persistent failures beyond service credits, where negotiable.

Follow-up that tests the answer: “If the proposed route becomes unavailable tomorrow, what money remains at risk, what can we stop paying, and what practical assistance must the counterparty provide?”

Evidence to request: A redlined issue register and exit-cost schedule. Model committed cash, remaining fees and transition effort separately; do not treat an indemnity as proof that losses will be recoverable.

Expert quote — reserved: ________________________________________

Sources cited on this page

  1. lilly.com · Source 1 ↗https://www.lilly.com/lillydirect/zepbound
Section sources →